Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Leases (2019 - 2025)

Anika Therapeutics (ANIK) has disclosed Current Leases for 7 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 6.99% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, up 6.99% year-over-year, with the annual reading at $2.1 million for FY2025, 6.99% up from the prior year.
  • Current Leases for Q4 2025 was $2.1 million at Anika Therapeutics, up from $1.7 million in the prior quarter.
  • The five-year high for Current Leases was $2.3 million in Q3 2024, with the low at $119000.0 in Q1 2021.
  • Average Current Leases over 5 years is $1.7 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Current Leases skyrocketed 1479.55% in 2023, then dropped 24.74% in 2025.
  • Over 5 years, Current Leases stood at $188000.0 in 2021, then soared by 1002.66% to $2.1 million in 2022, then fell by 11.87% to $1.8 million in 2023, then increased by 4.98% to $1.9 million in 2024, then rose by 6.99% to $2.1 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $2.1 million, $1.7 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.